Aarti Pharmalabs [AARTIPHARM] vs Hikal [HIKAL] Detailed Stock Comparison

Aarti Pharmalabs Ltd.

NSE
Loading...

Hikal Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Aarti Pharmalabs Ltd. wins in 13 metrics, Hikal Ltd. wins in 6 metrics, with 0 ties. Aarti Pharmalabs Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Aarti Pharmalabs Ltd. Hikal Ltd. Better
P/E Ratio (TTM) 29.41 257.60 Aarti Pharmalabs Ltd.
Price-to-Book Ratio 3.07 1.83 Hikal Ltd.
Debt-to-Equity Ratio 32.97 0.57 Hikal Ltd.
PEG Ratio -0.84 -1.91 Aarti Pharmalabs Ltd.
EV/EBITDA 17.17 9.24 Hikal Ltd.
Profit Margin (TTM) 11.87% 6.15% Aarti Pharmalabs Ltd.
Operating Margin (TTM) 17.05% 13.16% Aarti Pharmalabs Ltd.
EBITDA Margin (TTM) 17.05% 13.16% Aarti Pharmalabs Ltd.
Return on Equity 13.69% 7.19% Aarti Pharmalabs Ltd.
Return on Assets (TTM) 9.37% 3.59% Aarti Pharmalabs Ltd.
Free Cash Flow (TTM) $-1.12B $1.43B Hikal Ltd.
Dividend Yield 0.55% 0.49% Aarti Pharmalabs Ltd.
1-Year Return -27.61% -51.04% Aarti Pharmalabs Ltd.
Price-to-Sales Ratio (TTM) 3.49 1.92 Hikal Ltd.
Enterprise Value $69.01B $30.59B Aarti Pharmalabs Ltd.
EV/Revenue Ratio 3.83 1.66 Hikal Ltd.
Gross Profit Margin (TTM) 60.06% 52.72% Aarti Pharmalabs Ltd.
Revenue per Share (TTM) $199 $146 Aarti Pharmalabs Ltd.
Earnings per Share (Diluted) $23.56 $-1.06 Aarti Pharmalabs Ltd.
Beta (Stock Volatility) 0.11 N/A N/A

Aarti Pharmalabs Ltd. vs Hikal Ltd. Stock Performance Analysis

Loading Price Chart...

AARTIPHARM
HIKAL

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Aarti Pharmalabs Ltd.-0.08%5.66%-9.99%1.80%-15.40%-13.91%
Hikal Ltd.1.77%4.16%-7.05%10.64%-25.21%-17.48%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Aarti Pharmalabs Ltd.-27.61%62.73%147.07%147.07%147.07%147.07%
Hikal Ltd.-51.04%-42.23%-59.62%71.68%349.74%297.82%

Performance & Financial Health Analysis: Aarti Pharmalabs Ltd. vs Hikal Ltd.

MetricAARTIPHARMHIKAL
Market Information
Market Cap i₹62.82B₹23.07B
Market Cap CategoryMid capSmall cap
10 Day Avg. Volume i147,034270,350
90 Day Avg. Volume i193,883394,027
Last Close₹640.65₹187.25
52 Week Range₹585.00 - ₹971.00₹146.25 - ₹382.30
% from 52W High-34.02%-51.02%
All-Time High₹971.00 (Jul 16, 2025)₹742.00 (Aug 16, 2021)
% from All-Time High-34.02%-74.76%
Growth Metrics
Quarterly Revenue Growth-0.20%0.37%
Quarterly Earnings Growth-0.35%0.68%
Financial Health
Profit Margin (TTM) i0.12%0.06%
Operating Margin (TTM) i0.17%0.13%
Return on Equity (TTM) i0.14%0.07%
Debt to Equity (MRQ) i32.970.57
Cash & Liquidity
Book Value per Share (MRQ)₹225.70₹102.38
Cash per Share (MRQ)₹6.13N/A
Operating Cash Flow (TTM) i₹3.51B₹1.54B
Levered Free Cash Flow (TTM) i₹2.72B₹908.00M
Dividends
Last 12-Month Dividend Yield i0.55%0.49%
Last 12-Month Dividend i₹4.00₹1.00

Valuation & Enterprise Metrics Analysis: Aarti Pharmalabs Ltd. vs Hikal Ltd.

MetricAARTIPHARM (Apr 26, 2026)HIKAL (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i29.41257.60
Forward P/E iN/A23.10
PEG Ratio i-0.84-1.91
Price to Sales (TTM) i3.491.92
Price to Book (MRQ) i3.071.83
Market Capitalization
Market Capitalization i₹62.82B₹23.07B
Enterprise Value i₹69.01B₹30.59B
Enterprise Value Metrics
Enterprise to Revenue i3.831.66
Enterprise to EBITDA i17.179.24
Risk & Other Metrics
Beta i0.11N/A
Book Value per Share (MRQ) i₹225.70₹102.38

Financial Statements Comparison: Aarti Pharmalabs Ltd. vs Hikal Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricAARTIPHARM (2025)HIKAL (2025)
Revenue/Sales i20.86B18.44B
Cost of Goods Sold i12.18B8.75B
COGS % of Revenue i58.4%47.5%
Gross Profit i8.68B9.68B
Gross Margin i41.6%52.5%
Research & Development i328.32MN/A
Operating Income (EBIT) i3.77B1.95B
Operating Margin i18.1%10.6%
EBITDA i4.73B3.31B
EBITDA Margin i22.7%18.0%
Pre-Tax Income i3.61B1.24B
Pre-Tax Income % of Revenue i17.3%6.7%
Income Tax i882.85M330.00M
Income Tax % of Revenue i4.2%1.8%
Net Income (Profit) i2.72B908.00M
Profit Margin i13.1%4.9%

Balance Sheet & Liquidity Metrics

MetricAARTIPHARM (2025)HIKAL (2025)
Cash & Equivalents i67.34M130.00M
Total Current Assets i13.22B9.95B
Total Current Assets % of Revenue i63.4%54.0%
Total Current Liabilities i6.57B7.90B
Total Current Liabilities % of Revenue i31.5%42.8%
Long-Term Debt i1.23B3.70B
Long-Term Debt % of Revenue i5.9%20.0%
Total Shareholders Equity i19.90B12.62B
Retained Earnings i13.23B9.67B
Retained Earnings % of Revenue i63.4%52.5%
Property, Plant & Equipment i11.04B403.00M

Cash Flow Statement Comparison

MetricAARTIPHARM (2025)HIKAL (2025)
Operating Cash Flow i3.51B1.54B
Operating Cash Flow % of Revenue i16.8%8.4%
Capital Expenditures i-4.02B-1.36B
Free Cash Flow i-1.12B1.43B
FCF Margin i-5.4%7.8%
Debt Repayment iN/A-1.03B
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricAARTIPHARMHIKAL
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i90.66M123.30M
Float Shares i47.89M26.57M
% Held by Insiders i42.62%69.08%
% Held by Institutions i12.01%7.68%
% Held by Public i45.37%23.24%

Dividend Analysis & Yield Comparison: Aarti Pharmalabs Ltd. vs Hikal Ltd.

MetricAARTIPHARMHIKAL
Last 12-Month Dividend i₹4.00₹1.00
Last 12-Month Dividend Yield i0.55%0.49%
3-Year Avg Annual Dividend i₹3.17₹1.13
3-Year Avg Dividend Yield i0.27%0.19%
3-Year Total Dividends i₹9.50₹3.40
Ex-Dividend DateFeb 16, 2026Feb 17, 2026